A multicenter, randomized, double-blind, placebo-controlled trial to test efficacy and safety of magnetic resonance imaging-based thrombolysis in wake-up stroke (WAKE-UP)

Conflicts of interest: Matthias Endres has received grant support from AstraZeneca and Sanofi Aventis, has participated in advisory board meetings of Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, and Sanofi, and has received honoraria from AstraZeneca, Bayer, Berlin Chemie, Bristol-Myers Squibb, Boehringer Ingelheim, Desitin, Eisei, Ever, Glaxo Smith Kline, MSD, Novartis, Pfizer, Sanofi, Takeda, Trommsdorff. Jochen B. Fiebach has received fees as a board member, consultant, or lecturer from Boehringer Ingelheim, Lundbeck, Siemens, Sygnis, and Synarc. Jens Fiehler has received fees as a consultant or lecture fees from Codman, Covidien, Siemens, and Stryker. Christian Gerloff has received fees as a consultant or lecture fees from Bayer Vital, Boehringer Ingelheim, EBS technologies, Glaxo Smith Kline, Lundbeck, Pfizer, Sanofi Aventis, Silk Road Medical, and UCB. Ivana Galinovic has received lecture fees from Lundbeck. Keith W. Muir has received support for travel to meetings from Boehringer Ingelheim and has received consultancy fees from Codman. Salvador Pedraza has received fees as a board member, consultant, or lecturer from Lundbeck and Synarc. Vincent Thijs has received fees as a steering committee member, consultant, adjudicator, or lecturer from Boehringer Ingelheim,Sygnis, Bayer, Pfizer, Merck, Shire, Medtronic, Abbott, Takeda. Florent Boutitier, Bastian Cheng, Tae-Hee Cho, Martin Ebinger, Norbert Nighoghossian, Leif Østergaard, Josep Puig, Pascal Roy, Claus Z. Simonsen, and Götz Thomalla have no conflicts of interest to report.